ロード中...
OS8.1 A phase 0/2 clinical trial of a CDK4/6 inhibitor in aggressive meningioma patients
BACKGROUND: New approaches are urgently needed for aggressive meningiomas, which remain largely incurable. Forkhead Box M1 (FOXM1) has been identified as a master transcription factor in aggressive meningiomas and Cyclin D-dependent Kinases (CDK) are positive regulators of cell-cycle entry, promotin...
保存先:
| 出版年: | Neuro Oncol |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6795112/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.051 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|